Mubritinib

Mubritinib

Systematic (IUPAC) name
1-(4-{4-[(2-{(E)-2-[4-(trifluoromethyl)phenyl]ethenyl}-1,3-oxazol-4-yl)methoxy]phenyl}butyl)-1H-1,2,3-triazole
Clinical data
Pregnancy cat.	?
Legal status	Uncontrolled
Routes	Oral
Identifiers
CAS number	366017-09-6
ATC code	None
PubChem	CID 6444692
ChemSpider	4948554
UNII	V734AZP9BR Y
Chemical data
Formula	C25H23F3N4O2
Mol. mass	468.47 g/mol
SMILES	eMolecules & PubChem

Mubritinib (TAK-165) is a protein kinase inhibitor which was under development by Takeda for the treatment of cancer.^[1][2][3] It completed phase I clinical trials but appears to have been discontinued, as no new information on the drug has surfaced since December 2008.^[4]

Synthesis

See also

• Protein kinase inhibitor

References

1. ^ McCormick, Frank; Doriano Fabbro (2005). Protein Tyrosine Kinases: From Inhibitors to Useful Drugs (Cancer Drug Discovery and Development). Totowa, NJ: Humana Press. ISBN 1-58829-384-X. http://www.springerlink.com/content/k6q2t75544554204/. 
2. ^ Mitscher, Lester A.; Lednicer, Daniel (1977). The organic chemistry of drug synthesis. New York: Wiley. ISBN 0-470-10750-2. http://books.google.com/books?id=N6OAhuiHqiIC&lpg=PA108&pg=PA108#v=onepage&q&f=false. 
3. ^ Lednicer, Daniel (2008). Strategies for Organic Drug Synthesis and Design. New York: Wiley-Interscience. ISBN 0-470-19039-6. http://books.google.com/books?id=fEwl6Qev-mUC&lpg=PA311&pg=PA311#v=onepage&q&f=false. 
4. ^ "Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2 - Full Text View - ClinicalTrials.gov". http://clinicaltrials.gov/ct2/show/NCT00034281?term=TAK165&rank=1.